MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin

Completed
Conditions
Gastric or Duodenal Ulcers
Interventions
Drug: Lansoprazole
First Posted Date
2014-03-31
Last Posted Date
2016-11-04
Lead Sponsor
Takeda
Target Recruit Count
3366
Registration Number
NCT02099682

Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs

Completed
Conditions
Gastric or Duodenal Ulcers
Interventions
Drug: Lansoprazole
First Posted Date
2014-03-31
Last Posted Date
2016-10-27
Lead Sponsor
Takeda
Target Recruit Count
3502
Registration Number
NCT02099708

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

Completed
Conditions
Hypertension
Interventions
Drug: Azilsartan
First Posted Date
2014-03-31
Last Posted Date
2019-03-21
Lead Sponsor
Takeda
Target Recruit Count
387
Registration Number
NCT02100319

Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus

Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Pioglitazone/glimepiride
First Posted Date
2014-03-28
Last Posted Date
2016-04-15
Lead Sponsor
Takeda
Target Recruit Count
1168
Registration Number
NCT02098733

Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone

Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Pioglitazone/glimepiride
First Posted Date
2014-03-28
Last Posted Date
2016-10-18
Lead Sponsor
Takeda
Target Recruit Count
294
Registration Number
NCT02098746

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

Phase 1
Completed
Conditions
Gastroesophageal Reflux Disease
Erosive Esophagitis
Heartburn
Interventions
Drug: Dexlansoprazole
First Posted Date
2014-03-26
Last Posted Date
2015-03-06
Lead Sponsor
Takeda
Target Recruit Count
8
Registration Number
NCT02096458

Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Completed
Conditions
Hypertension
Interventions
Drug: Azilsartan
First Posted Date
2014-03-19
Last Posted Date
2019-01-15
Lead Sponsor
Takeda
Target Recruit Count
3437
Registration Number
NCT02092025

Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)

Completed
Conditions
Osteoporosis
Interventions
Drug: Sodium Risedronate
First Posted Date
2014-03-18
Last Posted Date
2018-10-19
Lead Sponsor
Takeda
Target Recruit Count
3304
Registration Number
NCT02089997

Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

Completed
Conditions
Advanced or Recurrent Colorectal Cancer
Interventions
Drug: Panitumumab
First Posted Date
2014-03-18
Last Posted Date
2017-04-06
Lead Sponsor
Takeda
Target Recruit Count
3091
Registration Number
NCT02089737

A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
Drug: Leuprorelin
Drug: Bicalutamide
First Posted Date
2014-03-12
Last Posted Date
2019-06-28
Lead Sponsor
Takeda
Target Recruit Count
116
Registration Number
NCT02085252
Locations
🇫🇷

Ouzid, Paris La Défense,, Paris, France

🇫🇷

Tenon Hospital Paris France, Paris, France

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy